cdk-9-in-2

CDK9-IN-2 is a specific CDK9 inhibitor with an IC50 of 5 nM in the A2058 skin cell line (72 hours) and 7 nM in the H929 multiple myeloma cell line (72 hours).

CKD-712 is a nuclear factor NF-kappa B inhibitor. CKD-712 suppressed MMP-9, but not MMP-2 and other NF-κB-regulated proteins involved in cancer metastasis such as VEGF. CKD-712 induced cell cycle arrest at G2M phase by suppressing cyclin A, cyclin B and C

CDK4 6-IN-14 is a potent, highly selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4 6), with inhibition concentrations (IC50s) of 10 nM and 16 nM, respectively. It shows over 60-fold selectivity for CDK4 6 compared to CDKs 1, 2, 7, and 9, and exhibits significant selectivity against 205 other kinases.

CDK2-IN-26, also known as compound 9, effectively inhibits CDK 2 [1].

CDK-IN-14 (Compound 9) serves as a potent and selective inhibitor of CDKL2 (Cyclin-dependent kinase-like 2), exhibiting an IC50 of 460 nM. Linked to biological processes such as tumor formation, development, and viral infections, CDKL2 is a substantial focus in the field. CDK-IN-14 holds promise as a powerful tool for the exploration of CDKL2s biological functions, potentially advancing research in areas like cancer and infectious diseases.